Why is Vaxcyte stock sliding in after-hours trading today?

Vaxcyte Inc. shares experienced a steep 5.8% drop in after-hours trading following the announcement of a $1 billion dual capital raise. The offering encompasses $500 million in common stock and pre-funded warrants, coupled with $500 million in convertible senior notes due in 2032. Underwriters retain the option to purchase $75 million in each tranche for a 30-day period, increasing the possibility of substantial share dilution.

This news follows Vaxcyte's announcement that its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, achieved all prespecified co-primary immunogenicity endpoints in the pivotal adult OPUS-1 Phase 3 trial. The trial involved over 4,000 participants across 30 U.S. sites, with all 28 serotypes shared with competitors meeting noninferiority criteria, and several unique VAX-31 serotypes demonstrating superiority.

Analysts praised the outcome, with Jefferies' Roger Song describing it as a "blue-sky" scenario and BTIG calling it a "clean sweep" of all 32 co-primary endpoints, maintaining a Buy rating with an $89 price target. Despite the positive intraday rally, the broader market remained unchanged, with the S&P 500, Dow Jones, and NASDAQ all finishing essentially flat.

The after-hours decline highlights the biotech industry's tendency to sell shares following well-received data, as companies use the elevated share price to fund future development and manufacturing scale-up.